The company has been plagued with issues at its Cordis medical device unit, which it bought for $1.9 billion in 2015 from Johnson & Johnson. The company had missed quarterly profit expectations in May due to inventory and cost issues at the unit.
Cardinal reported a fourth-quarter loss compared to a year-ago profit, as it took an asset-impairment charge of $1.35 billion primarily related to the unit's performance.
The company also issued forecast for fiscal year 2019 and said it expects adjusted earnings from continuing operations of $4.90 to $5.15 per share.
Net loss attributable to the company was $1.17 billion, or $3.76 per share, in the fourth quarter ended June 30, compared to a profit of $274 million, or 86 cents per share, a year earlier.
Excluding items, the company earned $1.01 per share, beating analysts' expectations of 93 cents, as per Thomson Reuters I/B/E/S.
Revenue rose 7.2 percent to $35.35 billion. (Reporting by Anuron Kumar Mitra and Tamara Mathias in Bengaluru; Editing by Shounak Dasgupta)